<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03133169</url>
  </required_header>
  <id_info>
    <org_study_id>GlnThalassemia</org_study_id>
    <nct_id>NCT03133169</nct_id>
  </id_info>
  <brief_title>Erythrocyte Glutamine/Glutamate Ratio Relation to Pulmonary Hypertension Risk in Thalassemic Children</brief_title>
  <official_title>Erythrocyte Glutamine/Glutamate Ratio Relation to Pulmonary Hypertension Risk in Thalassemic Children in Assiut University Children Hospital</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assiut University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assiut University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study will investigate the relation between erythrocyte glutamine/glutamate ratio and
      pulmonary hypertension risk in Egyptian thalassemic children in Assiut University Children
      Hospital
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">June 1, 2017</start_date>
  <completion_date type="Anticipated">June 1, 2018</completion_date>
  <primary_completion_date type="Anticipated">April 1, 2018</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Erythrocyte glutamine/glutamate ratio</measure>
    <time_frame>2 months</time_frame>
    <description>Biological marker for oxidative stress</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Tricuspid regurge velocity</measure>
    <time_frame>2 months</time_frame>
    <description>Measures the risk of pulmonary hypertension</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Plasma glutamine level</measure>
    <time_frame>2 months</time_frame>
    <description>Assess the glutamine level at each visit</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Liver function tests</measure>
    <time_frame>2 months</time_frame>
    <description>Evaluates the state of liver</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Renal function tests</measure>
    <time_frame>2 months</time_frame>
    <description>Evaluates the state of kidney</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Thalassemia in Children</condition>
  <condition>Pulmonary Hypertension</condition>
  <condition>Hemolysis</condition>
  <arm_group>
    <arm_group_label>Thalassemic patients</arm_group_label>
    <description>They will be investigated for erythrocyte glutamine/glutamate ratio and Tricuspid regurge velocity</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Erythrocyte glutamine/glutamate ratio</intervention_name>
    <description>Erythrocyte glutamine/glutamate ratio is a biomarker of oxidative stress. Will be obtained through examination of a blood sample</description>
    <arm_group_label>Thalassemic patients</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Tricuspid regurge velocity</intervention_name>
    <description>Tricuspid regurge velocity will be measured by doppler echocardiography denoting the pulmonary hypertension risk in children</description>
    <arm_group_label>Thalassemic patients</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Upper Egypt thalassemic children aged 10-18 years old attending Assiut University Children
        Hospital.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Established diagnosis of Thalassemia.

          -  PH risk documented by doppler echocardiography, defined as tricuspid regurge velocity
             (TRV) equal to or greater than 2.5 m/s

        Exclusion Criteria:

          -  Acute crisis or hospitalization within 1 month of enrollment

          -  Hepatic dysfunction (SGPT greater than 3X normal)

          -  Renal dysfunction (Creatinine greater than 2X normal)

          -  Patients on sildenafil (Viagra), calcium channel blockers or other drugs for the
             control of PH.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>10 Years</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Fahim M Fahim, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Children Hospital, Assiut University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Fatma S AbdElshafi, bachelor's</last_name>
    <role>Principal Investigator</role>
    <affiliation>Children Hospital, Assiut University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Eman F. Mohamed, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Children Hospital, Assiut University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Fatma S AbdElshafi, bachelor's</last_name>
    <phone>00201067116569</phone>
    <email>Fatma.s.hamdan@gmail.com</email>
  </overall_contact>
  <reference>
    <citation>Gladwin MT, Sachdev V, Jison ML, Shizukuda Y, Plehn JF, Minter K, Brown B, Coles WA, Nichols JS, Ernst I, Hunter LA, Blackwelder WC, Schechter AN, Rodgers GP, Castro O, Ognibene FP. Pulmonary hypertension as a risk factor for death in patients with sickle cell disease. N Engl J Med. 2004 Feb 26;350(9):886-95.</citation>
    <PMID>14985486</PMID>
  </reference>
  <reference>
    <citation>Morris CR, Kuypers FA, Kato GJ, Lavrisha L, Larkin S, Singer T, Vichinsky EP. Hemolysis-associated pulmonary hypertension in thalassemia. Ann N Y Acad Sci. 2005;1054:481-5.</citation>
    <PMID>16339702</PMID>
  </reference>
  <reference>
    <citation>Morris CR, Vichinsky EP. Pulmonary hypertension in thalassemia. Ann N Y Acad Sci. 2010 Aug;1202:205-13. doi: 10.1111/j.1749-6632.2010.05580.x.</citation>
    <PMID>20712794</PMID>
  </reference>
  <reference>
    <citation>Walter PB, Fung EB, Killilea DW, Jiang Q, Hudes M, Madden J, Porter J, Evans P, Vichinsky E, Harmatz P. Oxidative stress and inflammation in iron-overloaded patients with beta-thalassaemia or sickle cell disease. Br J Haematol. 2006 Oct;135(2):254-63.</citation>
    <PMID>17010049</PMID>
  </reference>
  <reference>
    <citation>Morris CR. Mechanisms of vasculopathy in sickle cell disease and thalassemia. Hematology Am Soc Hematol Educ Program. 2008:177-85. doi: 10.1182/asheducation-2008.1.177. Review.</citation>
    <PMID>19074078</PMID>
  </reference>
  <reference>
    <citation>Kuypers FA. Membrane lipid alterations in hemoglobinopathies. Hematology Am Soc Hematol Educ Program. 2007:68-73. Review.</citation>
    <PMID>18024611</PMID>
  </reference>
  <reference>
    <citation>Fung EB, Harmatz P, Milet M, Ballas SK, De Castro L, Hagar W, Owen W, Olivieri N, Smith-Whitley K, Darbari D, Wang W, Vichinsky E; Multi-Center Study of Iron Overload Research Group. Morbidity and mortality in chronically transfused subjects with thalassemia and sickle cell disease: A report from the multi-center study of iron overload. Am J Hematol. 2007 Apr;82(4):255-65.</citation>
    <PMID>17094096</PMID>
  </reference>
  <reference>
    <citation>Machado RF, Gladwin MT. Pulmonary hypertension in hemolytic disorders: pulmonary vascular disease: the global perspective. Chest. 2010 Jun;137(6 Suppl):30S-38S. doi: 10.1378/chest.09-3057.</citation>
    <PMID>20522578</PMID>
  </reference>
  <reference>
    <citation>Janda S, Shahidi N, Gin K, Swiston J. Diagnostic accuracy of echocardiography for pulmonary hypertension: a systematic review and meta-analysis. Heart. 2011 Apr;97(8):612-22. doi: 10.1136/hrt.2010.212084. Epub 2011 Feb 25. Review. Erratum in: Heart. 2011 Jul;97(13):1112.</citation>
    <PMID>21357375</PMID>
  </reference>
  <reference>
    <citation>De Castro LM, Jonassaint JC, Graham FL, Ashley-Koch A, Telen MJ. Pulmonary hypertension associated with sickle cell disease: clinical and laboratory endpoints and disease outcomes. Am J Hematol. 2008 Jan;83(1):19-25.</citation>
    <PMID>17724699</PMID>
  </reference>
  <reference>
    <citation>Anthi A, Machado RF, Jison ML, Taveira-Dasilva AM, Rubin LJ, Hunter L, Hunter CJ, Coles W, Nichols J, Avila NA, Sachdev V, Chen CC, Gladwin MT. Hemodynamic and functional assessment of patients with sickle cell disease and pulmonary hypertension. Am J Respir Crit Care Med. 2007 Jun 15;175(12):1272-9. Epub 2007 Mar 22.</citation>
    <PMID>17379852</PMID>
  </reference>
  <reference>
    <citation>Hebbel RP. Reconstructing sickle cell disease: a data-based analysis of the &quot;hyperhemolysis paradigm&quot; for pulmonary hypertension from the perspective of evidence-based medicine. Am J Hematol. 2011 Feb;86(2):123-54. doi: 10.1002/ajh.21952. Review.</citation>
    <PMID>21264896</PMID>
  </reference>
  <reference>
    <citation>Morris CR. Vascular risk assessment in patients with sickle cell disease. Haematologica. 2011 Jan;96(1):1-5. doi: 10.3324/haematol.2010.035097.</citation>
    <PMID>21193426</PMID>
  </reference>
  <reference>
    <citation>Mok E, Hankard R. Glutamine supplementation in sick children: is it beneficial? J Nutr Metab. 2011;2011:617597. doi: 10.1155/2011/617597. Epub 2011 Nov 14.</citation>
    <PMID>22175008</PMID>
  </reference>
  <reference>
    <citation>Xu H, Pearl RG. Effect of l-glutamine on pulmonary hypertension in the perfused rabbit lung. Pharmacology. 1994 Apr;48(4):260-4.</citation>
    <PMID>8177911</PMID>
  </reference>
  <reference>
    <citation>Morris CR, Suh JH, Hagar W, Larkin S, Bland DA, Steinberg MH, Vichinsky EP, Shigenaga M, Ames B, Kuypers FA, Klings ES. Erythrocyte glutamine depletion, altered redox environment, and pulmonary hypertension in sickle cell disease. Blood. 2008 Jan 1;111(1):402-10. Epub 2007 Sep 11.</citation>
    <PMID>17848621</PMID>
  </reference>
  <reference>
    <citation>Niihara Y, Matsui NM, Shen YM, Akiyama DA, Johnson CS, Sunga MA, Magpayo J, Embury SH, Kalra VK, Cho SH, Tanaka KR. L-glutamine therapy reduces endothelial adhesion of sickle red blood cells to human umbilical vein endothelial cells. BMC Blood Disord. 2005 Jul 25;5:4.</citation>
    <PMID>16042803</PMID>
  </reference>
  <reference>
    <citation>Machado RF, Farber HW. Pulmonary hypertension associated with chronic hemolytic anemia and other blood disorders. Clin Chest Med. 2013 Dec;34(4):739-52. doi: 10.1016/j.ccm.2013.08.006. Epub 2013 Oct 17. Review.</citation>
    <PMID>24267302</PMID>
  </reference>
  <verification_date>April 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 15, 2017</study_first_submitted>
  <study_first_submitted_qc>April 25, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">April 28, 2017</study_first_posted>
  <last_update_submitted>April 25, 2017</last_update_submitted>
  <last_update_submitted_qc>April 25, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 28, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Assiut University</investigator_affiliation>
    <investigator_full_name>Fatma Sami</investigator_full_name>
    <investigator_title>Pediatric Resident</investigator_title>
  </responsible_party>
  <keyword>Thalassemia</keyword>
  <keyword>Glutamine/glutamate ratio</keyword>
  <keyword>Pulmonary hypertension</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Hypertension, Pulmonary</mesh_term>
    <mesh_term>Thalassemia</mesh_term>
    <mesh_term>Hemolysis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

